US Biologic
- Company typePrivate
- Founded2012
- HeadquartersMemphis, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What US Biologic does
US Biologic, Inc. is a privately held Memphis-based biotechnology company founded in 2012 that develops and commercializes orally delivered vaccines and biologics through its proprietary OrisBio platform. The company's core commercial product is the LymeShield System, which combines a USDA-conditionally licensed Borrelia Burgdorferi Bacterin oral wildlife vaccine (spray-coated onto pellets consumed by white-footed mice) with tick and rodent control methods and targeted delivery stations, designed to interrupt Lyme disease transmission at the animal reservoir. The OrisBio platform encompasses species-specific substrates, bacterial expression vehicles, and chemical encapsulation components that enable thermostable, needle-free oral delivery to wildlife, companion animals, food animals, and humans across multiple formulation types including kibble, chewables, effervescent tablets, and powders.
US Biologic's business model is anchored by channel-based distribution of the LymeShield System through pest management professional (PMP) companies across 15 states in the upper northeast, Midwest, and Atlantic Seaboard, with strategic anchor partnerships including JP McHale Pest Management. The company also pursues enterprise relationships with federal agencies (USDA, CDC, BARDA DRIVe, DHS Plum Island), state health departments, and universities for co-development of pipeline products. Pipeline assets include a chewable human flu vaccine (BARDA DRIVe partnership under the Beyond the Needle program), cNK-2 oral antibiotic alternative for poultry coccidiosis (USDA ARS partnership), anti-tick vaccines (USDA ARS and East Stroudsburg University), and oral vaccines for Peste des Petits Ruminants, African Swine Fever, Classical Swine Fever, and Foot & Mouth Disease. Revenue is generated via product sales (quote-based through PMP and government channels) supplemented by non-dilutive federal grant funding from USDA SBIR/NIFA and BARDA DRIVe.
The company has assembled a board and advisory team with notable public-health and industry credentials, including a former CDC Director and USAMRIID Chief, a former U.S. DHHS Secretary, and the retired Chairman/CEO of Sanofi Pasteur. US Biologic is mid-scale-up of its Memphis operations, executing a four-phase manufacturing and headquarters expansion totaling approximately 80,000 sq ft and $96 million of investment through 2028, with 110 jobs planned. The intellectual property portfolio spans 12 patents (4 granted) and registered trademarks for OrisBio and LymeShield.
US Biologic firmographics
Firmographics- Name
- US Biologic
- Legal name
- US Biologic, Inc.
- Website
- https://usbiologic.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
US Biologic industry classification
Industry- Product category
- Animal Health Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Veterinary Vaccines (Biologics) (HLAMAEAL)
- akta.pro secondary industries
- Wildlife & Zoo/Exotic Animal Vaccines (HLAMAKAG), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)
Keywords
Where US Biologic is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
US Biologic business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Oral Wildlife Vaccines (LymeShield): Sale of LymeShield oral vaccine products distributed through pest management professionals for residential, public lands, and commercial settings. Conditionally licensed by USDA.
- Food Animal Vaccines: Oral vaccines for poultry (coccidiosis), cattle (Peste des Petits Ruminants), and swine (African Swine Fever, Classical Swine Fever, Foot & Mouth Disease) delivered through government and commercial channels.
- Human Health Vaccines (Pipeline): Chewable oral flu vaccines being developed with BARDA DRIVe for home delivery. Planned to be reformulated for multiple species including birds, cattle, swine, and wildlife.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
US Biologic product offering
Product offeringCore offering
US Biologic develops and commercializes orally delivered vaccines and biologics that prevent zoonotic diseases at their animal source using its proprietary OrisBio platform. Its flagship commercial product, the LymeShield System, combines tick and rodent control with a USDA conditionally licensed oral vaccine (Borrelia Burgdorferi Bacterin) that immunizes white-footed mice against Lyme disease. The company also advances a chewable flu vaccine with BARDA DRIVe and an oral antibiotic alternative (cNK-2) for poultry with USDA ARS.
Product overview
US Biologic is a biotechnology company developing and commercializing orally delivered vaccines and biologics for disease prevention. The company's portfolio centers on the LymeShield System (including the USDA-conditionally licensed Borrelia Burgdorferi Bacterin vaccine) for Lyme disease prevention, and the OrisBio oral-delivery platform enabling species-specific vaccine delivery. Development-stage products include a chewable flu vaccine (BARDA DRIVe partnership) and cNK-2 antibiotic alternative for poultry (USDA ARS partnership). Products span wildlife, companion animals, food animals, and humans with emphasis on thermostable, needle-free oral delivery.
Differentiator
Problem solved
Functional benefit
Brands
- LymeShield System: Integrated tick management program consisting of an oral wildlife vaccine (Borrelia Burgdorferi Bacterin) spray-coated on pellets consumed by mice, designed to prevent Lyme disease transmission at the animal source. Includes tick and rodent control methods and a delivery station device.
- OrisBio
- cNK-2
Products and services
- LymeShield System An Integrated Pest Management program featuring vaccine-coated pellets that inoculate white-footed mice against Lyme disease, combined with tick and rodent control methods and delivery stations. The product is sold to pest-management professionals, government agencies, and public-lands operators for deployment in residential, commercial, golf course, and public-land settings to break the Lyme infection cycle at the animal source.
- Borrelia Burgdorferi Bacterin Vaccine USDA conditionally licensed oral wildlife vaccine, spray-coated onto pellets that white-footed mice consume, delivering immunity against Borrelia burgdorferi (the Lyme disease bacterium). Used as the vaccine component within the LymeShield System and distributed to pest-management professionals and government agencies for tick-borne disease intervention.
Quantifiable outcome
- 74% reduction in tick infection rates over 5 years in Dutchess County field trials with Cary Institute of Ecosystem Studies
- +5 more outcomes
Companies that use US Biologic
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
US Biologic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
US Biologic partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and secondary.
- USDA Agricultural Research Service (ARS)coreUS Biologic and USDA ARS jointly developed cNK-2, an oral alternative to antibiotics for poultry coccidiosis. Project funded by USDA's National Institute of Food and Agriculture under the Small Business Innovation Research Program. Partnership also includes vaccines against Peste des Petits Ruminants and anti-tick vaccines.
- JP McHale Pest ManagementcoreStrategic partnership with Buchanan, NY-based pest management company to launch LymeShield System in Westchester, Hudson Valley, and nationwide. JP McHale deploys US Biologic's oral mouse vaccine through its technician network to combat Lyme disease surge.
- Dr. Jane Huffman Wildlife Genetics Institute at East Stroudsburg University of PennsylvaniasecondaryPartnership to conduct field trials for new anti-tick vaccine to complement the LymeShield System.
- BARDA DRIVe (Biomedical Advanced Research and Development Authority, Division of Research, Innovation, and Ventures)coreUS Biologic and BARDA DRIVe are co-developing an oral flu vaccine that doesn't require refrigeration or needles and can be delivered to homes. Partnership is part of BARDA's Beyond the Needle program to develop needle-free vaccine alternatives. BARDA DRIVe is part of the U.S. Department of Health and Human Services.
- Department of Homeland Security Plum Island Animal Disease CentercorePartnership for development of vaccines against African Swine Fever, Classical Swine Fever, and Foot & Mouth Disease through the DHS Science & Technology Directorate.
- University of EdinburghsecondaryPartnership to develop vaccines against Peste des Petits Ruminants in cattle using oral delivery technology.
- Cary Institute of Ecosystem StudiessecondaryFive-year field study in Dutchess County showed 74% decrease in tick infection rates using US Biologic's oral Lyme vaccine. Cary Institute collaborated on real-world field trials demonstrating vaccine efficacy.
- Global Lyme AlliancesecondaryNon-profit partner collaborating on Lyme disease education materials and advocacy. GLA Chairman Paul Ross echoed support for wildlife-based disease prevention approaches.
- Center for Lyme Actionsecondary501c4 advocacy organization dedicated to growing federal funding for Lyme and tick-borne conditions. Co-founder Bonnie Crater provided roadmap for Delaware legislation and additional state initiatives.
- University of Tennessee Health Science Center (UTHSC)coreDr. Maria Gomes-Solecki, inventor of the oral vaccination technology, is a professor at UTHSC. US Biologic maintains R&D team at UTHSC and collaborated on technology transfer from research to commercialization.
- State of DelawaresecondaryDelaware passed HB404 bill creating Lyme and tick-borne disease intervention fund overseen by Department of Agriculture, supporting US Biologic's wildlife-based prevention approach on state-owned lands.
- National Institute of Antimicrobial Resistance Research and Education (NIAMRRE)secondaryNIAMRRE Executive Director Dr. Paul Plummer called the cNK-2 research 'a promising advance in improving antibiotic stewardship' and preserving antibiotic use for future generations.
Scale indicators6 records
Recent moves7 records
Expansion highlights7 records
US Biologic competitors and assessment
Company assessmentDirect peers
- Zoetis: The world's largest animal health company and a leading manufacturer of veterinary vaccines and biologics for livestock and companion animals. Directly comparable as a developer and commercializer of veterinary vaccines across multiple species—the same end markets US Biologic targets with OrisBio.
- Merck Animal Health: A leading manufacturer of veterinary vaccines, parasiticides, and biologics for livestock, poultry, and companion animals. Directly comparable as a multi-species animal vaccine developer with established federal and commercial distribution relationships.
- Boehringer Ingelheim Animal Health: One of the top global animal health companies with a broad veterinary vaccines and biologics portfolio across livestock, swine, and poultry. Directly comparable in livestock/swine vaccine development and global animal-health commercialization infrastructure.
- Elanco Animal Health: Global animal health company with a meaningful livestock, poultry, and companion-animal vaccine portfolio. Directly comparable as a multi-species vaccine developer and commercializer, particularly relevant to US Biologic's poultry coccidiosis program.
- HIPRA: Spanish veterinary biopharmaceutical company specializing in vaccines for livestock and aquaculture. Directly comparable as a focused animal-vaccine specialist developing novel biologics for food-animal infectious diseases, similar in profile to US Biologic's pipeline positioning.
- Ceva Santé Animale: Global veterinary pharmaceutical company with a strong vaccines portfolio for poultry, swine, and ruminants. Directly comparable in multi-species livestock vaccine R&D and commercialization, particularly relevant to US Biologic's PPR and swine disease programs.
- Phibro Animal Health: Animal health and nutrition company with vaccines and antibiotic alternatives for livestock and poultry. Comparable as a developer of antibiotic-alternative biologics and livestock vaccines, particularly relevant to US Biologic's cNK-2 antimicrobial-resistance positioning.
- Virbac: Global animal health company with a veterinary vaccines and biologics portfolio across livestock and companion animals. Comparable as a multi-species animal vaccine developer with similar commercialization channels into food-animal producers.
Emerging players
- Valneva: Specialty vaccine company developing a human Lyme disease vaccine (VLA15) partnered with Pfizer. Comparable as a Lyme-disease vaccine developer addressing the same target market US Biologic approaches via wildlife intervention; emerges from a different mechanism but addresses the same disease burden.
- Tarsus Pharmaceuticals: Late-stage biopharmaceutical company developing therapeutics for tick-borne diseases including Lyme. Comparable as a newer entrant addressing the same tick-borne disease market US Biologic targets, although with a human-pharmaceutical rather than wildlife-vaccine approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
US Biologic social profiles
Digital presenceUS Biologic compliance and trust
Trust signalCompliance1 record
US Biologic financial estimates
Financial estimateRevenue estimate
Valuation estimate
US Biologic leadership team
Management profileNumber of profiles
Profiles14 records
US Biologic funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
US Biologic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about US Biologic
What does US Biologic do?
US Biologic develops and commercializes orally delivered vaccines and biologics that prevent zoonotic diseases at their animal source using its proprietary OrisBio platform. Its flagship commercial product, the LymeShield System, combines tick and rodent control with a USDA conditionally licensed oral vaccine (Borrelia Burgdorferi Bacterin) that immunizes white-footed mice against Lyme disease. The company also advances a chewable flu vaccine with BARDA DRIVe and an oral antibiotic alternative (cNK-2) for poultry with USDA ARS.
Is US Biologic a public or private company?
US Biologic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was US Biologic founded?
US Biologic was founded in 2012. It employs 1 to 10 people.
Where is US Biologic based?
US Biologic is headquartered in Memphis, United States, in the North America region.
How does US Biologic make money?
Three revenue lines are on record. Oral Wildlife Vaccines (LymeShield) is the primary driver. The others are food Animal Vaccines and human Health Vaccines (Pipeline).
Who are US Biologic's main competitors?
Direct peers on record are Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, HIPRA, Ceva Santé Animale, Phibro Animal Health and Virbac. Emerging players are Valneva and Tarsus Pharmaceuticals.
Does US Biologic have an API?
No public API is recorded for US Biologic.
What industry is US Biologic in?
US Biologic's product category is Animal Health Biologics. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAG, Wildlife & Zoo/Exotic Animal Vaccines. Its NAICS code is 325414 and its SIC code is 2836.